Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
persistent opioid exposure in older adults with rheumatic disease national patterns disparities and cross specialty prescribing
Original title: “Persistent Opioid Exposure in Older Adults with Rheumatic Disease: National Patterns, Disparities, and Cross-Specialty Prescribing.”
protocol for the development of a paediatric core outcome set for arthrogryposis multiplex congenita an international multi interest holder consensus study
Original title: “Protocol for the development of a paediatric core outcome set for arthrogryposis multiplex congenita: an international multi-interest-holder consensus study.”
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Original title: “HR 10810: National Patient Safety Board Act of 2026”
Few patients who receive tumor-infiltrating lymphocyte therapy for advanced melanoma experience serious treatment-related adverse events after discharge. An evaluation of more than 50 individuals who received tumor-infiltrating lymphocyte (TIL) therapy at Memorial Sloan Kettering Cancer Center ... Few patients who receive tumor-infiltrating lymphocyte therapy for advanced melanoma experience serious treatment-related adverse events after discharge. An evaluation of more than 50 individuals who received tumor-infiltrating lymphocyte (TIL) therapy at Memorial Sloan Kettering Cancer Center showed only two developed grade 3 or 4 treatment-related adverse events after their release, and only How are they ambulating? These are basic clinical issues to look out for. “At our center, we start out by following people two times a week, and then we are able to space it out further from there. I know some patients travel a great distance for their TIL therapy. Patients with advanced melanoma treated with TIL therapy rarely develop grade 3 or 4 treatment-related adverse events after discharge. “A lot of them have high burdens of disease coming into TIL, and we know that the response to lifileucel is only around 30%. Unfortunately, a majority of patients who go through this process will have disease progression, and we found that the majority of new adverse events, new readmissions, were more likely to be related to disease progression than a new side effect related to lifileucel.” · Additionally, 12 patients needed at least one blood product transfusion, nine of whom needed one within 30 days of discharge. Among these patients, 10 received packed red blood cells and six needed them within 30 days. “That encompasses a range of different clinical profiles, and this idea of prolonged cytopenias is something we need to do more research on,” Smithy said.
Original title: “Serious treatment-related adverse events after discharge for TIL therapy rare”
lymphangiogenesis driven by vegf c reshapes tumor immune landscape and enables tumor eradication by viral immunotherapy in mouse melanoma models
Original title: “Lymphangiogenesis driven by VEGF-C reshapes tumor immune landscape and enables tumor eradication by viral immunotherapy in mouse melanoma models.”
improving clinical research through better use of clinical trial registry data
Original title: “Improving clinical research through better use of clinical trial registry data.”
genomic clinical and radiological characterization of spontaneous cervical artery dissections findings from a single center cohort
Original title: “Genomic, clinical, and radiological characterization of spontaneous cervical artery dissections: Findings from a single-center cohort.”
adult onset still disease flare 5 days following poly l lactic acid injection a cautionary tale for aesthetic practice
Original title: “Adult-onset Still Disease Flare 5 Days Following Poly-l-lactic Acid Injection: A Cautionary Tale for Aesthetic Practice.”
survival by design cell fate dynamics in classical hodgkin lymphoma
Original title: “Survival by Design: Cell Fate Dynamics in Classical Hodgkin Lymphoma.”
The Food and Drug Administration (FDA or the Agency) is announcing the issuance of four Emergency Use Authorizations (EUA or Authorization) under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for new animal products. FDA has issued one EUA for an animal product as requested by Elanco US Inc. for application on or around wounds for the prevention of infestations caused by New World screwworm (Cochliomyia hominivorax; NWS) larvae (myiasis) in sheep, cattle, goats, swine, camelids, and the fo
Original title: “Authorization of Emergency Use for Four Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability”
azathioprine versus mycophenolate mofetil in treatment naive autoimmune hepatitis 3 year follow up of the camaro trial
Original title: “Azathioprine versus mycophenolate mofetil in treatment-naive autoimmune hepatitis: 3-year follow-up of the CAMARO-trial.”
post transplant lymphoproliferative disorder after successful treatment of graft versus host disease following liver transplantation
Original title: “Post-Transplant Lymphoproliferative Disorder After Successful Treatment of Graft-Versus Host Disease Following Liver Transplantation.”
initial treatment strategies and outcomes across haemodynamic thresholds and risk stratification in incident systemic sclerosis associated pulmonary arterial hypertension a eustar analysis
Original title: “Initial treatment strategies and outcomes across haemodynamic thresholds and risk stratification in incident systemic sclerosis-associated pulmonary arterial hypertension: a EUSTAR analysis.”
spinal neurocysticercosis synthesizing evidence on clinical presentations anatomical patterns diagnostic approaches and therapeutic strategies
Original title: “Spinal neurocysticercosis: synthesizing evidence on clinical presentations, anatomical patterns, diagnostic approaches, and therapeutic strategies.”
dynamic bronchoscopic evolution of a cobblestone like appearance in covid 19 associated pulmonary aspergillosis a case report
Original title: “Dynamic Bronchoscopic Evolution of a Cobblestone-like Appearance in COVID-19-associated Pulmonary Aspergillosis: A Case Report.”
recommendations of the groupe francophone des my lodysplasies gfm diagnostic approach and management of myelodysplastic syndromes chronic myelomonocytic leukemias and vexas syndrome
Original title: “[Recommendations of the Groupe Francophone des Myélodysplasies (GFM) - Diagnostic approach and management of myelodysplastic syndromes, chronic myelomonocytic leukemias, and VEXAS syndrome].”
definition of childhood visual impairment a systematic overview of reviews and authoritative sources across clinical research and policy contexts
Original title: “Definition of childhood visual impairment: A systematic overview of reviews and authoritative sources across clinical, research, and policy contexts.”